Should Your Business Be Worried About Twitter Blue?

 

Twitters initial effort to charge money to verify accounts with a blue check mark is a mess, costing companies millions and damaging stock prices immensely. Videographer and Social Media Analyst Jordan Fussell highlights those companies most effected by such an influx in believable fake Twitter accounts.

Jordan’s Thoughts:

“Now, being a person who grew up on the internet, one of the things that you’ll learn early on is that people love to pretend to be somebody else, like Michael Jackson or a prince who wants to send you his entire fortune if you’ll only send him about $500 in Target gift card, So the internet did what the internet do and proceeded to make multiple parody accounts, famous companies, and tweet out ridiculous things they would never say.

But by far, one of the most damaging was a parody account of the company, Eli Lilly, an American Pharmaceutical Company, who is responsible for a large production of insulin. And they tweeted out, “Exciting news! Insulin is now free for everyone,” and because of that verified check mark next to their name, proceeded this in the internet into a spiral.

Now the actual Eli Lilly Twitter account was able to do some damage control, but not before the company dropped. 10 points on Friday, which at the time of this recording, the company is still not recovered from. I believe the main takeaway from all of this is that Musk and Twitter need to crack down on a plan to not have somebody with $8 in a sense of humor, cost investors thousands of dollars for the push of a single button.”

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More